Lupin launches bioequivalent Glucagon for Injection for severe hypoglycaemia and diagnostics, targeting $122 million U.S. market.

• Treats severe hypoglycaemia in diabetic adults and children, and reduces gastrointestinal motility during radiologic examinations.
• Glucagon emergency kit, 1 mg/vial, generated $122 million annual U.S. sales according to IQVIA MAT June 2025.
• Lupin, headquartered in Mumbai, distributes branded, generic, biotech, and API products to over 100 markets globally.